Oxycodone-induced analgesic effects in a bone cancer pain model in mice

Oncology

Volumn 74, Issue SUPPL.1, 2008, Pages 55-60

  Kato, Akira ^a   Minami, Kazuhisa ^a   Ito, Hisanori ^a   Tomii, Takako ^a   Matsumoto, Mitsunobu ^a   Orita, Satoshi ^a   Kihara, Tsuyoshi ^a   Narita, Minoru ^b   Suzuki, Tsutomu ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Bone cancer pain; Femur bone cancer; Fentanyl; Morphine; Oxycodone

Indexed keywords

FENTANYL CITRATE; MORPHINE; OXYCODONE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; BONE CANCER; CANCER GROWTH; CANCER MODEL; CANCER PAIN; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMUR; IMAGING SYSTEM; LOCOMOTION; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR CELL;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; FENTANYL; LUCIFERASES; MALE; MICE; MICE, INBRED C3H; MORPHINE; NEOPLASMS, EXPERIMENTAL; OSTEOLYSIS; OXYCODONE; PAIN;

EID: 50849136181     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000143220     Document Type: Conference Paper

References (23)

1. Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, Borsodi A: Opioid binding profiles of new hydrazone, oxyme, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 1999;64:2011-2020.
2. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 2006;316:1195-1201.
3. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, Suzuki T: Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 2008;33:1097-1112.
4. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 2006;105:801-812.
5. Lemberg K, Kontinen VK, Viljakka K, Kylänlahti I, Yli-Kauhaluoma J, Kalso E: Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 2006;102:1768-1774.
6. Nozaki C, Saitoh A, Kamei J: Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol 2006;535:145-151.
7. Mercadante S, Arcuri E: Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998;24:425-432.
8. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-134.
9. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW: Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-10897.
10. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H: The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg 2000;75:16-26.
11. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Lugar NM, Mach DB, Schwei MJ, Sevcik MA, Mantyh PW: Tumor-induced injury of primary afferent sensory nerve fivers in bone cancer pain. Exp Neurol 2005;193:85-100.
12. Bercovitch M, Adunsky A: High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 2006;20:33-39.
13. Honore P, Lugar NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, O'keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-528.
14. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW: Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 2002;99:397-406.
15. Vermeirsch H, Nuydens RM, Salmon PL, Meert TF: Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol Biochem Behav 2004;79:243-251.
16. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW: Anti-NGF therapy profoundly reduces bone caner pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-141.
17. Gilchrist LS, Cain DM, Harding-Rose C, Kov AN, Wendelschafer-Crabb G, Kennedy WR, Simone DA: Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Res 2005;1044:197-205.
18. Arnér S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1998;33:11-23.
19. Stanfa L, Dickenson A: Spinal opioid systems in inflammation. Inflamm Res 1995;44:231-241.
20. Bridges D, Thompson SWN, Rice ASC: Mechanisms of neuropathic pain. Br J Anaesth 2001;87:12-26.
21. El Mouedden M, Meert TF: Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav 2005;82:109-119.
22. El Mouedden M, Meert TF: The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone caner pain. Pharmacol Biochem Behav 2007;87:30-40.
23. Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, Pasternak GW: Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 2005;68:866-875.